DK0433827T3 - Cytotoksisk lumfocytmodningsfaktor - Google Patents

Cytotoksisk lumfocytmodningsfaktor

Info

Publication number: DK0433827T3
Authority: DK; Denmark
Prior art keywords: clmf; cells; proteins; relates; present
Prior art date: 1989-12-22

Application number

DK90123670T

Other languages

English (en)

Inventor

Richard Anthony Chizzonite

Maurice Kent Gately

Ulrich Andreas Gubler

Jeffrey David Hulmes

Yu-Ching Eugene Pan

Frank John Podlaski

Alvin Seth Stern

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-22

Filing date

1990-12-09

Publication date

1998-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27412641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0433827(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-12-09 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1998-09-28 Application granted granted Critical

1998-09-28 Publication of DK0433827T3 publication Critical patent/DK0433827T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Transplantation (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK90123670T 1989-12-22 1990-12-09 Cytotoksisk lumfocytmodningsfaktor DK0433827T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US45570889A	1989-12-22	1989-12-22
US52093590A	1990-05-09	1990-05-09
US57228490A	1990-08-27	1990-08-27

Publications (1)

Publication Number	Publication Date
DK0433827T3 true DK0433827T3 (da)	1998-09-28

Family

ID=27412641

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK97104656T DK0790255T3 (da)	1989-12-22	1990-12-09	Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
DK97104682T DK0790308T3 (da)	1989-12-22	1990-12-09	Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod
DK90123670T DK0433827T3 (da)	1989-12-22	1990-12-09	Cytotoksisk lumfocytmodningsfaktor
DK97104860T DK0790309T3 (da)	1989-12-22	1990-12-09	Cytotoksisk 40kD underenhed af lymfocytmodningsfaktor og monoklonale antistoffer rettet derimod

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK97104656T DK0790255T3 (da)	1989-12-22	1990-12-09	Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
DK97104682T DK0790308T3 (da)	1989-12-22	1990-12-09	Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK97104860T DK0790309T3 (da)	1989-12-22	1990-12-09	Cytotoksisk 40kD underenhed af lymfocytmodningsfaktor og monoklonale antistoffer rettet derimod

Country Status (11)

Country	Link
EP (4)	EP0433827B1 (da)
JP (2)	JP3238418B2 (da)
AT (4)	ATE369383T1 (da)
AU (2)	AU6834990A (da)
BG (1)	BG60933B2 (da)
CA (3)	CA2572802A1 (da)
DE (4)	DE69034244T2 (da)
DK (4)	DK0790255T3 (da)
HU (1)	HU211879A9 (da)
IE (1)	IE904694A1 (da)
NZ (1)	NZ236545A (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5456924A (en) *	1988-12-23	1995-10-10	Immunotec Research Corporation Ltd.	Method of treatment of HIV-seropositive individuals with dietary whey proteins
US5811523A (en)	1988-11-10	1998-09-22	Trinchieri; Giorgio	Antibodies to natural killer stimulatory factor
US5457038A (en) *	1988-11-10	1995-10-10	Genetics Institute, Inc.	Natural killer stimulatory factor
EP0375045A1 (en) *	1988-12-22	1990-06-27	Duphar International Research B.V	New annelated indole derivatives
US6683046B1 (en)	1989-12-22	2004-01-27	Hoffmann-La Roche Inc.	Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6706264B1 (en)	1994-03-14	2004-03-16	Genetics Institute, Llc	Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) *	1994-03-14	1995-10-10	Genetics Inst	Use of interleukin-12 antagonists in the treatment of autoimmune diseases
ES2297831T3 (es)	1994-05-09	2008-05-01	Oxford Biomedica (Uk) Limited	Vectores retroviricos que presentan una tasa de recombinacion reducida.
AU695129B2 (en) *	1995-02-06	1998-08-06	Genetics Institute, Llc	Formulations for IL-12
US5891680A (en) *	1995-02-08	1999-04-06	Whitehead Institute For Biomedical Research	Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
GB9505784D0 (en) *	1995-03-22	1995-05-10	Lynxvale Ltd	Anti-tumour treatment
US5853714A (en) *	1995-03-27	1998-12-29	Genetics Institute, Inc.	Method for purification of IL-12
US5880146A (en) *	1995-06-07	1999-03-09	Fuji Immunopharmaceuticals Corporation	Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
US5853697A (en) *	1995-10-25	1998-12-29	The United States Of America, As Represented By The Department Of Health & Human Services	Methods of treating established colitis using antibodies against IL-12
GB9609932D0 (en) *	1996-05-13	1996-07-17	Hoffmann La Roche	Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP0850951A4 (en) *	1996-06-04	2001-04-11	Juridical Foundation	NEW FELINE CYTOKINE PROTEIN
JP2001503258A (ja) *	1996-10-18	2001-03-13	バレンティス・インコーポレーテッド	遺伝子発現および搬送系および用途
JP2001503257A (ja) *	1996-10-18	2001-03-13	バレンティス・インコーポレーテッド	Ｉｌ―１２遺伝子発現および送達系および使用
US6054487A (en) *	1997-03-18	2000-04-25	Basf Aktiengesellschaft	Methods and compositions for modulating responsiveness to corticosteroids
WO1998041229A1 (en) *	1997-03-19	1998-09-24	F. Hoffmann-La Roche Ag	USE OF IL-12p40 AS IMMUNOSTIMULANT
JP2002241398A (ja) *	1997-06-03	2002-08-28	Chemo Sero Therapeut Res Inst	新規なイヌサイトカインタンパク質
US6060284A (en)	1997-07-25	2000-05-09	Schering Corporation	DNA encoding interleukin-B30
ES2590912T3 (es)	1997-12-08	2016-11-24	Merck Patent Gmbh	Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US7026456B1 (en)	1998-01-23	2006-04-11	Hoffman-La Roche, Inc.	Antibodies against human IL-12
SK782002A3 (en)	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja)	1999-08-09	2011-10-12	メルクパテントゲーエムベーハー	複合サイトカイン−抗体複合体
WO2001018051A2 (en) *	1999-09-09	2001-03-15	Schering Corporation	Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
AU2005202420B2 (en) *	1999-09-09	2008-08-07	Merck Sharp & Dohme Corp.	Mammalian cytokines; related reagents and methods
EP3184637A1 (en) *	1999-09-09	2017-06-28	Merck Sharp & Dohme Corp.	Mammalian interleukin-12 p40 and interleukin b30 complexes, antibodies, uses in pharmaceutical compositions
US7090847B1 (en)	1999-09-09	2006-08-15	Schering Corporation	Mammalian cytokines; related reagents and methods
EP1228214A2 (en)	1999-11-12	2002-08-07	MERCK PATENT GmbH	Erythropoietin forms with improved properties
US7115712B1 (en)	1999-12-02	2006-10-03	Maxygen, Inc.	Cytokine polypeptides
ATE336514T1 (de)	2000-02-11	2006-09-15	Merck Patent Gmbh	Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
RU2272644C2 (ru)	2000-06-29	2006-03-27	Мерк Патент Гмбх	Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US6902734B2 (en)	2000-08-07	2005-06-07	Centocor, Inc.	Anti-IL-12 antibodies and compositions thereof
DK1366067T3 (da)	2001-03-07	2012-10-22	Merck Patent Gmbh	Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en)	2001-03-30	2006-01-31	Emd Lexigen Research Center Corp.	Reducing the immunogenicity of fusion proteins
US6969517B2 (en)	2001-05-03	2005-11-29	Emd Lexigen Research Center Corp.	Recombinant tumor specific antibody and use thereof
BR0214650A (pt)	2001-12-04	2005-05-03	Merck Patent Gmbh	Imunocitoquinas com seletividade modulada
ATE471946T1 (de)	2002-12-17	2010-07-15	Merck Patent Gmbh	Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
JP2007517506A (ja)	2004-01-05	2007-07-05	イーエムディー・レキシゲン・リサーチ・センター・コーポレーション	標的化用化合物
EP1836294A4 (en)	2004-12-21	2009-06-17	Centocor Inc	ANTI-IL-12 ANTIBODIES, EPITOPES, COMPOSITIONS, METHODS AND USES
CA2635618C (en)	2005-12-30	2015-10-06	Merck Patent Gesellschaft Mit Beschraekter Haftung	Interleukin-12p40 variants with improved stability
JP2011504740A (ja)	2007-11-27	2011-02-17	アブリンクスエン．ヴェー．	ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
US7891807B2 (en) *	2009-06-11	2011-02-22	Ana Nichole Mansuy	Decorative eyeglass temples
JP7468992B2 (ja)	2016-03-29	2024-04-16	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２及び／又は－２３抗体の増加した間隔投与による乾癬の処置
US10189151B2 (en)	2016-11-14	2019-01-29	Snap-On Incorporated	Compact head body hammer
TW201922780A (zh) *	2017-09-25	2019-06-16	美商健生生物科技公司	以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
JP7421500B2 (ja)	2018-05-18	2024-01-24	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
FI3883606T3 (fi)	2018-09-24	2023-09-07	Janssen Biotech Inc	Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella
MX2021014302A (es)	2019-05-23	2022-01-04	Janssen Biotech Inc	Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
WO2021234634A1 (en)	2020-05-21	2021-11-25	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5457038A (en) *	1988-11-10	1995-10-10	Genetics Institute, Inc.	Natural killer stimulatory factor
EP0441900B1 (en) *	1988-11-10	1996-07-17	Genetics Institute, Inc.	Natural killer stimulatory factor

1990
- 1990-12-09 DK DK97104656T patent/DK0790255T3/da active
- 1990-12-09 DK DK97104682T patent/DK0790308T3/da active
- 1990-12-09 AT AT97104656T patent/ATE369383T1/de not_active IP Right Cessation
- 1990-12-09 EP EP90123670A patent/EP0433827B1/en not_active Expired - Lifetime
- 1990-12-09 DK DK90123670T patent/DK0433827T3/da active
- 1990-12-09 DK DK97104860T patent/DK0790309T3/da active
- 1990-12-09 AT AT90123670T patent/ATE163675T1/de not_active IP Right Cessation
- 1990-12-09 DE DE69034244T patent/DE69034244T2/de not_active Revoked
- 1990-12-09 EP EP97104656A patent/EP0790255B1/en not_active Revoked
- 1990-12-09 DE DE69034249T patent/DE69034249T2/de not_active Revoked
- 1990-12-09 EP EP97104682A patent/EP0790308B1/en not_active Revoked
- 1990-12-09 AT AT97104860T patent/ATE368112T1/de not_active IP Right Cessation
- 1990-12-09 EP EP97104860A patent/EP0790309B1/en not_active Revoked
- 1990-12-09 DE DE69034247T patent/DE69034247T2/de not_active Revoked
- 1990-12-09 AT AT97104682T patent/ATE366311T1/de not_active IP Right Cessation
- 1990-12-09 DE DE69032086T patent/DE69032086T2/de not_active Expired - Lifetime
- 1990-12-19 CA CA002572802A patent/CA2572802A1/en not_active Abandoned
- 1990-12-19 CA CA002032653A patent/CA2032653C/en not_active Expired - Lifetime
- 1990-12-19 CA CA002346997A patent/CA2346997C/en not_active Expired - Lifetime
- 1990-12-19 NZ NZ236545A patent/NZ236545A/xx unknown
- 1990-12-20 AU AU68349/90A patent/AU6834990A/en not_active Abandoned
- 1990-12-21 IE IE469490A patent/IE904694A1/en not_active IP Right Cessation
- 1990-12-22 JP JP41325990A patent/JP3238418B2/ja not_active Expired - Lifetime
1994
- 1994-01-25 AU AU54712/94A patent/AU674363B2/en not_active Expired
- 1994-03-01 BG BG098632A patent/BG60933B2/bg unknown
1995
- 1995-06-20 HU HU95P/P00267P patent/HU211879A9/hu unknown
2001
- 2001-08-14 JP JP2001246031A patent/JP3375949B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NZ236545A (en)	1993-04-28
DE69034247D1 (de)	2007-09-06
ATE368112T1 (de)	2007-08-15
BG60933B2 (bg)	1996-06-28
EP0790308A1 (en)	1997-08-20
JP3238418B2 (ja)	2001-12-17
DE69034249D1 (de)	2007-09-20
JP2002167400A (ja)	2002-06-11
EP0790255A3 (en)	2000-03-01
IE904694A1 (en)	1991-07-17
JPH05294999A (ja)	1993-11-09
DE69034244D1 (de)	2007-08-16
CA2032653A1 (en)	1991-06-23
AU674363B2 (en)	1996-12-19
EP0790309A1 (en)	1997-08-20
DE69034244T2 (de)	2008-04-03
DK0790309T3 (da)	2007-11-05
AU6834990A (en)	1991-06-27
ATE366311T1 (de)	2007-07-15
EP0790255A2 (en)	1997-08-20
IE990006A1 (en)	2000-11-01
EP0433827B1 (en)	1998-03-04
DK0790255T3 (da)	2007-11-26
CA2346997A1 (en)	1991-06-23
HU211879A9 (en)	1995-12-28
ATE163675T1 (de)	1998-03-15
DE69034247T2 (de)	2008-04-17
EP0790309B1 (en)	2007-07-25
JP3375949B2 (ja)	2003-02-10
EP0433827A2 (en)	1991-06-26
CA2572802A1 (en)	1991-06-23
DE69032086D1 (de)	1998-04-09
DK0790308T3 (da)	2007-10-08
CA2346997C (en)	2007-02-20
ATE369383T1 (de)	2007-08-15
DE69034249T2 (de)	2008-05-29
EP0790308B1 (en)	2007-07-04
IE990007A1 (en)	2000-11-01
CA2032653C (en)	2002-05-28
AU5471294A (en)	1994-06-09
IE990005A1 (en)	2000-11-01
EP0790255B1 (en)	2007-08-08
DE69032086T2 (de)	1998-09-17
EP0433827A3 (en)	1992-07-01

Publication	Publication Date	Title
DK0433827T3 (da)	1998-09-28	Cytotoksisk lumfocytmodningsfaktor
DE69332413D1 (de)	2002-11-21	Interleukin-2 analoge mit niedriger toxizität zur verwendung in der immuntherapie
DE3789859D1 (de)	1994-06-23	Formen des Koloniestimulierungsfaktors 1.
EP0156355A3 (en)	1987-09-02	Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
ATE103494T1 (de)	1994-04-15	Verwendung von interleukin 2 zur behandlung von leukaemien.
ATE167519T1 (de)	1998-07-15	T-zellen-wachstumsfaktor
IL102346A0 (en)	1993-01-14	Cysteine depleted il-6 muteins
Nishihara et al.	1988	Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide
EP0248583A3 (en)	1989-10-18	Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
Ottmann et al.	1987	Proliferative effects of a recombinant human granulocyte colony-stimulating factor (rg-CSF) on highly enriched hematopoietic progenitor cells
Schrader et al.	1982	Molecular classification of T-cell-derived lymphokines
BG60657B2 (en)	1995-11-30	Human recombinant interleukin-2 muteins
ES8703928A1 (es)	1987-03-01	Un metodo para preparar la proteina factor de estimulacion de colonias (csf-1)recombinante